Sign in Subscribe

Agios Wins FDA Priority Review for First Oral PK Activator in Sickle Cell Disease

PDUFA target date is November 1, 2026. If approved, it would be the first oral PK activator for SCD patients.

Agios Wins FDA Priority Review for First Oral PK Activator in Sickle Cell Disease
Credit: Agios Pharmaceuticals
Already have an account? Sign in.